Episodes of TG-induced toxicities requiring switch to MP
| . | C/IM 1* . | DI 1* . | IM 2* . | DI 2* . | Maint 1-4 . | Maint > 4* . | Total (%†) . |
|---|---|---|---|---|---|---|---|
| VOD | 16 | 13 | 23 | 11 | 119 | 24 | 206 (80) |
| DT | 0 | 0 | 0 | 0 | 28 | 23 | 51 (20) |
| Total (%†) | 16 (6.2) | 13 (5.0) | 23 (8.9) | 11 (4.3) | 147 (57.3) | 47 (18.3) | 257 (100) |
| . | C/IM 1* . | DI 1* . | IM 2* . | DI 2* . | Maint 1-4 . | Maint > 4* . | Total (%†) . |
|---|---|---|---|---|---|---|---|
| VOD | 16 | 13 | 23 | 11 | 119 | 24 | 206 (80) |
| DT | 0 | 0 | 0 | 0 | 28 | 23 | 51 (20) |
| Total (%†) | 16 (6.2) | 13 (5.0) | 23 (8.9) | 11 (4.3) | 147 (57.3) | 47 (18.3) | 257 (100) |
Data represent number and percentage of episodes of VOD or DT by treatment phase.
C/IM indicates consolidation/interim maintenance; DI, delayed intensification (TG 60 mg/m2 per day for 14 days); and maint, maintenance.
Primarily boys, treated 1 year longer than girls.
Reflects percentage of total episodes.